Standardized, risk-adapted induction therapy in kidney transplantation

Area of Science:

• Nephrology
• Immunology
• Transplantation Medicine

Background:

• Kidney transplant induction therapy selection is often non-standardized and varies by center.
• Clinicians choose between depleting and non-depleting antibodies, impacting immunosuppression and infection risk.
• A standardized, risk-stratified algorithm is proposed to balance rejection and infection risks.

Purpose of the Study:

• To implement and evaluate a standardized, risk-stratified algorithm for induction therapy in kidney transplantation.
• To assess the impact of this protocol on rejection rates, allograft survival, and infection complications.
• To provide an individualized approach to induction therapy selection based on immunologic risk factors.

Main Methods:

• Patients undergoing kidney transplantation were stratified into low, intermediate, or high immunologic risk categories.
• Induction therapy was administered based on risk: basiliximab (low), antithymocyte globulin (intermediate), or low-dose alemtuzumab (high).
• Outcomes including rejection rates, allograft survival, estimated glomerular filtration rate (eGFR), and infection types were analyzed after 3 years.

Main Results:

• 126 patients were stratified (69 low, 42 intermediate, 15 high risk) with a median follow-up of 1.9 years.
• No significant differences in rejection rates or 3-year allograft survival were observed among the risk groups.
• While viral and bacterial infections did not differ, opportunistic fungal infections were more frequent with alemtuzumab induction.

Conclusions:

• The risk-stratified induction therapy strategy facilitates individualized treatment choices in kidney transplantation.
• The protocol demonstrated comparable efficacy across risk groups regarding rejection and survival.
• Further prospective trials are recommended to validate this risk-stratified algorithm.